Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 419 participants.

Also called NCT04857840

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 419 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04857840
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT04857840. Randomized; double masking; primary purpose treatment. Start 2021-08-05 (actual); primary completion 2023-01-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)
Acronym
REFRESH
Condition
Hypertension (HTN)
Intervention (Drug)
Firibastat (QGC001) Period 1
Lead sponsor
Quantum Genomics SA (class: industry)
Collaborator
PRA Health Sciences (class: industry)

Record details

Record id
cardio:ct-nct04857840
Content hash
57abacfc1a2e7c3e9dc9e9e4a1b72df6978b9acb49ca06c80be5891ce004d26f